Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

Update: 2025-07-29

Description

touchEXPERT FOCUS for touchNEUROLOGY and touchCARDIO

Listen to Dr Chafic Karam share expert insights on diagnosing and managing ATTRv amyloidosis. In this short interview, he covers red-flag symptoms, diagnostic challenges and key strategies for differentiating ATTRv. He also discusses current treatment options, including TTR stabilisers and gene silencers, as well as emerging therapies aimed at improving patient outcomes.

The expert:

Dr Chafic Karam, University of Pennsylvania, Philadelphia, PA, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our websites:

https://touchneurology.com/ and https://touchcardio.com/

Comments

In Channel

Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies?

2025-09-1037:39

$Phacoemulsification in cataract surgery: Evolving options to optimize refractive outcomes$

Phacoemulsification in cataract surgery: Evolving options to optimize refractive outcomes

2025-09-1041:04

Stargardt disease: Improving awareness, diagnosis and patient support

2025-08-2737:53

Mastering DKA management: From pathophysiology to prevention and ketone monitoring strategies

2025-08-2628:39

A case-based discussion on PAH: Optimizing early detection, risk stratification and treatment decision-making

2025-08-2137:53

Continuous glucose monitoring for cardiovascular risk reduction: The next frontier in preventive care

2025-08-2028:07

HER2 as a targetable biomarker in gastrointestinal oncology

2025-08-1935:30

Navigating the evolving role of immunotherapy in advanced endometrial carcinoma

2025-07-3143:31

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

2025-07-2919:06

Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

2025-07-0901:09:32

Advancing care for patients with infantile haemangiomas: Timing is key

2025-07-0717:14

Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

2025-06-2635:34

Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease

2025-06-2536:07

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

2025-06-2316:33

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

2025-06-2316:33

Towards personalized care for people living with HIV: Supporting open dialogue and informed treatment choices

2025-06-1934:02

RET-positive NSCLC: Translating insights into targeted approaches

2025-05-1514:36

RET-positive NSCLC: Translating insights into targeted approaches

2025-05-1514:36

Advances in dry eye disease: From diagnosis to new treatment targets

2025-05-0837:43

Recent advances in the care of patients with geographic atrophy: Bringing new and emerging therapies into focus

2025-05-0635:33

00:00

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

#box-pro-ellipsis-17579892169459{-webkit-line-clamp:2;}Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

touchpodcast

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease